Engineered immune cells take aim at childhood cancer
NCT ID NCT02311621
First seen May 21, 2026 · Last updated Jun 23, 2026 · Updated 8 times
Summary
This early-stage trial tests a new approach for children and young adults with neuroblastoma that has come back or not responded to standard treatments. Doctors take a patient's own immune cells (T-cells), genetically modify them in the lab to recognize and attack a protein called CD171 found on neuroblastoma cells, and then infuse them back into the patient. The main goal is to find a safe dose and watch for side effects, while also checking if the treatment can shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GANGLIONEUROBLASTOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Seattle Children's Hospital
Seattle, Washington, 98105, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
genetically modified T-cells (CAR T-cells) targeting CD171
What this could lead to
If successful, this could lead to a new treatment option for children with hard-to-treat neuroblastoma that has not responded to standard therapy.
What could go wrong
This is an early phase 1 trial focused on safety and dosing, so it is too soon to know if it will work. There are risks of serious side effects from the modified cells, and the treatment may not shrink tumors.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.